• Voyageur Pharmaceuticals entered a non-dilutive collaboration and funding agreement with Bayer tied to an iodine extraction feasibility program.
• First milestone met with Bayer’s acceptance of a feasibility work plan, triggering a USD 1 million payment on Sept. 10, 2026.
• Total Bayer funding received reached USD 1.35 million, including an initial USD 350,000 paid on March 31, 2026.
• Second USD 1 million milestone payment is expected upon completion of the FEL-3 feasibility study, supported by pilot-plant field data.
• Parties may later negotiate a long-term offtake deal targeting up to 1,000 tonnes per year of iodine supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyageur Pharmaceuticals Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202609100930TNWSWRCACNPR_____1L5PFrZl8) on September 10, 2026, and is solely responsible for the information contained therein.